Chinese Phase I Clinical Trial of HIV Vaccine Concluded
Phase I of a three-phase clinical trial for an experimental HIV vaccine launched last year in Nanning, China, concluded on Sunday after researchers finished follow-up examinations of the 49 participants who received the vaccine Xinhua/People's Daily reports (Xinhua/People's Daily, 6/11). The trial participants, ages 18 to 50, were given either a single experimental HIV vaccine or a combined vaccine between March and October 2005 (Kaiser Daily HIV/AIDS Report, 4/3). "Currently, data based on clinical observations have shown everything is normal, and we are confident that the AIDS vaccine is safe," Chen Jie, deputy director of the country's Center for Disease Control in Guangxi, said (Xinhua/People's Daily, 6/11). The Ministry of Science and Technology and the State Food and Drug Administration will decide whether to go forward with a Phase II trial of the vaccine based on an assessment of the Phase I trial (Kaiser Daily HIV/AIDS Report, 4/3). The assessment will include immunization procedures, appropriate dose level and safety of the vaccine, and whether the trials are meeting China's clinical research safety standards, according to Chen (Xinhua/People's Daily, 6/11).This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.